Publications

Molecular typing and antimicrobial susceptibility of vancomycin-resistant Enterococcus faecium in Brazil. by Cereda RF, Gales AC, Silbert S, Jones RN and Sader HS published in Infect. Control. Hosp. Epidemiol. 2002; 23 (1): 19-22

Pharmacodynamics in the evaluation of drug regimens. by Bhavnani SM, Ambrose PG and Jones RN published in Ann. Pharmacother. 2002; 36 (3): 530-532

Prevalence of extended spectrum β-lactamase (ESBL)-producing clinical isolates in the Asia-Pacific region and South Africa: Regional results from SENTRY Antimicrobial Surveillance Program (1998-99). by Bell JM, Turnidge JD, Gales AC, Pfaller MA and Jones RN published in Diagn. Microbiol. Infect. Dis. 2002; 42 (3): 193-198

Pharmacodynamic considerations in the treatment of moderate to severe pseudomonal infections with cefepime. by Ambrose PG, Owens RC, Jr., Garvey MJ, and Jones RN published in J. Antimicrob. Chemother. 2002; 49 (3): 445-453

BMS284756 Potency And Spectrum Tested Against Over 10,000 Bacterial Blood Stream Infection Isolates from the SENTRY Antimicrobial Surveillance Program (2000), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Ertapenem (MK- 0826) Potency and Spectrum Tested Alone and in Combinations Against 902 Drug-Resistant Isolates, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Activity and Spectrum Evaluation of Dalbavancin, A Novel “Glycopeptide” Class Antimicrobial, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Re-evaluation of Recommended Cefditoren MIC Quality Control Ranges for Four ATCC Strains, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Multi-resistant Escherichia coli from Urinary Tract Infection in the Western Pacific: Results from SENTRY Western Pacific Plus (WP+) 1998-2000 John Turnidge Women’s and Children’s Hospital, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Major Regional Variation in Haemophilus influenzae Resistance in the Western Pacific: Results from SENTRY Western Pacific Plus (WP+) 1998-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Surveillance in Taiwan Using Molecular Epidemiology for Extended-Spectrum &#223-Lactamase (ESBL)-Producing K. pneumoniae (KPN), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Evaluation of Six Broad-Specrum ß-Lactams Tested Against Recent Clinical Isolates from India: A 10 Medical Center Survey, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Antimicrobial Potenty and spectrum for Ro63-9141 (RO), a Novel Cephalosporin with Activity Against Methicillin-Resistant Staphylococci (MRS), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Initial Determinations of Susceptibility Testing Interpretive Criteria and Quality Control Guidelines for Tiamulin, A Pleuromutilin Derivative Used in Veterinary Practice, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Anti-streptococcal activity of AZD2563, a new oxazolidinone antimicrobial agent, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

In vitro antimicrobial activity of AZD2563, a novel oxazolidinone, tested against Staphylococcus aureus and coagulase-negative staphylococci, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

In vitro evaluation of AZD2563, a new oxazolidinone, tested against unusual Gram-positive species tested against unusual Gram- positive species, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Antimicrobial Susceptibility and Pharmacodynamic Comparison of Cefepime and Piperacillin-Tazobactam Against Enterobacteriaceae Producing Extended-Spectrum &#223-Lactamase, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Meropenem Yearly Susceptibility Test Information Collection (MYSTIC) program, USA: Trends in resistance, molecular epidemiology and antimicrobial usage, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Multicenter Assessment of Linezolid Spectrum and Potency in the United States Using the Standardized Disk Diffusion Method: Report From the Zyvox ® Antimicrobial Potency Study (KB-ZAPS), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Molecular Epidemiology of Inducible Macrolide Resistance in Staphylococcus aureus in the Western Pacific: Results from SENTRY Western Pacific Plus (WP+) 1998-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Quality Control Evaluation of BMS-284756 (T-3811ME) 5-mg Disk Diffusion (DD) and MIC Testing, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

In-vitro Activity of BMS-284756 (T-3811ME), a des-F(6)-Quinolone, Against Organisms Collected in the SENTRY (2000) European Susceptibility Study, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

BMS-284756 (T-3811ME) Susceptibility Test Comparisons and Development for More Than 30 Bacterial Species Using 3,328 Recent Clinical Isolates, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Extended Spectrum Beta-Lactamase (ESBL) Phenotypes In Enteric Bacilli from the Asia-Pacific Region: Report from the SENTRY Antimicrobial Surveillance Program, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Antifungal Activity of Posaconazole, Ravuconazole, and Voriconazole Compared to that of Itraconazole and Amphotericin B Against 239 Clinical Isolates of Aspergillus spp. and other Filamentous Fungi: Report from SENTRY Program, 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Species Distribution and Antifungal Susceptibility (AFS) Patterns for Candida Bloodstream Isolates from the SENTRY Participants Group [Europe] 1999 – 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antifungal Susceptibility of Candida spp. Isolated from Pediatric and Adult Patients with Blood Stream Infections: SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Patients with Blood Stream Infections (BSI) in North America (NA): SENTRY Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Extreme Variations in Susceptibility (S) of P. aeruginosa (PSA) Among Hospitals in North America (NA), Latin America (LA), Europe (EU) and the Asia-Pacific (AP): Report from the SENTRY Antimicrobial Surveillance Program, 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Frequency of Occurrence of Bacterial Pathogens in Bacteremic Infections and Antimicrobial Susceptibility From the SENTRY Surveillance Programme in Europe 2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Regional Variations and Trends in Antimicrobial Resistance Among E. faecalis (EF) and E. faecium (EFM) in the Global SENTRY Antimicrobial Surveillance Program (1997-2000), presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Pediatric and Adult Patients with Blood Stream Infections in North America: SENTRY 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Trends in Antimicrobial Susceptibility of Bacterial Pathogens Isolated from Pediatric and Adult Patients with Blood Stream Infections in North America: SENTRY 1997-2000, presented at 41st annual Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC), December, 2001, Chicago, Illinois

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against H. influenzae and M. catarrhalis, Including In Vitro Test Development Comparisons, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Staphylococci and Enterococci, Including In Vitro Test Development and Comparisons, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Streptococci, Including In Vitro Test Comparisons and Development, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Streptococci, Including In Vitro Test Comparisons and Development, presented at International Congress of Chemotherapy, June 30 – July 3, 2001, Amsterdam, The Netherlands

Comparative Activity Of Gatifloxacin Against S. pneumoniae, H. influenzae, and M. catarrhalis Before (1997-99) and During (2000) the Clinical Release in North America (NA): A SENTRY Antimicrobial Surveillance Program Report, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 Against 2,681 Recent Clinical Isolates of Haemophilus influenzae and Moraxella catarrhalis: Report from the SENTRY Antimicrobial Surveillance Program (2000) in Europe, Canada and the US, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Activity and Spectrum of BMS 284756 Tested Against 3546 Strains of Ciprofloxacin-Resistant Gram-Positive Cocci, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Against Neisseria gonorrhoeae, Including In Vitro Test Comparisons and Development BMS284756 MIC ( m m g/ ml), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Activity Of BMS284756, A Novel Desfluoroquinolone, Against Streptococci, Including Initial In Vitro Test Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Geographic Variations in BMS 284756 Activity Against Pathogens Associated with Skin and Soft Tissue Infections: Report from the SENTRY Antimicrobial Surveillance Program (2000), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Geographic Variations in BMS284756 Activity and Spectrum Tested Against Common Respiratory Tract Pathogens: Report from the SENTRY Antimicrobial Surveillance Program (2000), presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) Tested Against Enteric Bacilli, Including In Vitro Test Comparisons and Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity of BMS284756 (T-3811; A Desfluoroquinolone) AgainstThree Groups of Non-fermentative Gram-negative Bacilli, Including In Vitro Test Comparisons And Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Comparative Antimicrobial Spectrum and Activity Of BMS 284756 (T-3811; A Desfluoroquinolone) Trend Against Anaerobes and Selected Fastidious Species (Campylobacter, Helicobacter, Legionella), Including Limited In Vitro Methods Development, presented at 7th annual International Symposium on New Quinolones, June 10 – 13, 2001, Edinburgh, Scotland

Ability of the Latin America Centers to Detect Antimicrobial Resistance Patterns: Experience of SENTRY Surveillance Antimicrobial Program 1997-1999, presented at 101st annual American Society for Microbiology General Meeting (ASM), May 20-24, 2001, Orlando, Florida

Importance of Non-Fermentative Gram-Negative Bacilli (NFB) Causing Serious Infections: Geographic Patterns, Epidemiological Features, and Trends in the SENTRY Antimicrobial Surveillance Program (1997-1999), presented at 101st annual American Society for Microbiology General Meeting (ASM), May 20-24, 2001, Orlando, Florida